Lacosamide: An Adjunctive Agent for Partial-Onset Seizures and Potential Therapy for Neuropathic Pain

Abstract

Spanish

French

Objective:

To review the pharmacology, pharmacokinetics, efficacy, and safety of lacosamide, a new agent for use as adjunctive treatment in partial-onset seizures and a potential agent for treatment of neuropathic pain.

Data Sources:

A MEDLINE search (1966–July 2009) was conducted using the key words lacosamide, harkoseride, SPM-927, ADD-234037, epilepsy, anticonvulsant, and neuropathic pain. Bibliographies of all articles retrieved were also reviewed.

Study Selection and Data Extraction:

All studies including humans and published in English with data describing lacosamide for the adjunctive treatment of partial-onset seizures and for treatment of neuropathic pain were reviewed.

Data Synthesis:

Lacosamide is a functionalized amino acid molecule that selectively enhances the slow inactivation of voltage-gated sodium channels and interacts with the collapsin-response mediator protein-2. With its bioavailability of approximately 100%, minimal protein binding, and few drug–drug interactions, lacosamide has a favorable pharmacokinetic profile. Recent data suggest that lacosamide may have a role as adjunctive treatment of partial-onset seizures. Open-label studies showed a 14-47% reduction in seizure frequency, while placebo-controlled trials demonstrated a 26-40% reduction in seizure frequency. The 50% responder rates ranged from 32.7% to 41.2% with varying doses of lacosamide. Although lacosamide use is not approved by the Food and Drug Administration for treatment of neuropathic pain, studies demonstrated reductions of 2.01–3.60 in pain scale scores. The most common adverse effects, occurring in greater than 10% of subjects in the clinical trials, include arthralgia, ataxia, blurred vision, diplopia, dizziness, fatigue, headache, injection site pain (only in intravenous studies), nausea, tremor, upper respiratory tract infection, and vomiting.

Conclusions:

Lacosamide is an effective agent for adjunctive treatment of refractory partial-onset seizures. Its exact role in the treatment of neuropathic pain needs to be determined.

Keywords

lacosamide neuropathic pain partial-onset seizures

Get full access to this article

View all access options for this article.

References

Chang

Lowenstein

. Epilepsy. N Engl J Med 2003;349:1257–66.

Kwan

Brodie

. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–9.

Garnett

. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;20: 191S–9S.

Errington

Stohr

Heers

Lees

. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157–69.

Beyreuther

Freitag

Heers

Krebsfanger

Scharfenecker

Stohr

. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:21–42.

Beydoun

D'souza

Hebert

Doty

. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33–42.

Bailer

Johannessen

Kupferberg

Levy

Perucca

Tomson

. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73:1–52.

Kehne

Kane

Chaney

. Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res 1997;27:41–54.

Fountain

French

Privitera

. Harkoseride: safety and tolerability of a new antiepileptic drug (AED) in patients with refractory partial seizures (abstract). Epilepsia 2000;41(suppl 7): 169–70.

10.

Sachdeo

Montouris

Beydoun

. An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures (abstract). Neurology 2003;60(suppl 1):A433.

11.

Chung

Sperling

Biton

Krauss

Beaman

Hebert

. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures (abstract). Epilepsia 2007;48(S6):321.

12.

Ben-Menachem

Biton

Jatuzis

Abou-Khalil

Doty

Rudd

. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308–17.

13.

Halasz

Kalviainen

Mazurkiewicz-Beldzinska

. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443–53.

14.

Krauss

Ben-Menachem

Mameniskiene

Vaiciene

Brock

Whitesides

. Intravenous lacosamide (SPM 927) as replacement for oral lacosamide in subjects with partial seizures: a multicenter, open-label, inpatient safety and tolerability trial (abstract). Epilepsia 2006;47(suppl 4):163.

15.

Biton

Rosenfeld

Whitesides

Fountain

Vaiciene

Rudd

. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008;49:418–24.

16.

Shaibani

Biton

Rauck

Koch

Simpson

. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur J Pain 2009;13:458–63.

17.

Rauck

Shaibani

Biton

Simpson

Koch

. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007;23:150–8.

18.

McCleane

Koch

Rauschkolb

. A report of continuing analgesia after 12 months treatment with SPM 927 in six subjects with neuropathic pain. J Neuropathic Pain Symptom Palliation 2005;1:25–8.

19.

Bretschneider

Bongardt

Koch

. A multi-center, open-label, follow-on trial to assess the long-term safety and efficacy of lacosamide in subjects with painful diabetic neuropathy (abstract). J Pain 2006;7: S43.

20.

Hidvegi

Bretschneider

Thierfelder

Sommerville

Bongardt

. Long-term efficacy of lacosamide in subjects with painful distal diabetic neuropathy (abstract). J Pain 2008;9: P27.

21.

McCleane

Koch

Rauschkolb

. Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study. Neurosci Lett 2003;352:117–20.

22.

Graf

Frye

Simpson

. Lacosamide in long-term treatment of painful diabetic neuropathy (DNP) (abstract). Eur J Neurol 2007;14(suppl 1):260.

23.

Bongardt

Shaibani

Kenney

Simpson

. Lacosamide in painful distal diabetic neuropathy: results of a multi-center, placebo-controlled US trial (abstract). Eur J Neurol 2007;14(suppl 1):250.

24.

Wymer

Garrison

Simpson

Koch

. A multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of lacosamide in painful distal diabetic neuropathy (abstract). Ann Neurol 2006;60(suppl 3):S68.

25.

Biton

. Lacosamide for the treatment of diabetic neuropathic pain. Expert Rev Neurother 2008;8:1649–60.

26.

Vorchheimer

. What is QT prolongation? J Fam Pract 2005 Jun;Suppl S4-7.

27.

Package insert. Vimpat (lacosamide tablets and injection) Smyrna, GA: UCB, Inc., October 2008.

28.

Lacosamide for epilepsy. Med Lett Drugs Ther 2009; 51: 50–2.

29.

Cardinal Health. www.cardinal.com (accessed 2009 May 22).